Safety & Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular

Status Completed

Clinical Trial Summary

The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, Nerinetide (NA-1), in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct core and with good collateral circulation who are selected for endovascular revascularization.

Clinical Trial Description

Trial Objectives: The primary objective is to determine the efficacy of the neuroprotectant, Nerinetide, in reducing global disability in subjects with major acute ischemic stroke (AIS) with a small established infarct core and with good collateral circulation selected for rapid endovascular revascularization. The secondary objectives are to determine the efficacy of Nerinetide in: - Reducing functional dependence - Improving neurological outcome - Improving activities of daily living - Reducing mortality rate The leading safety objectives are to determine the effect of administering a dose of 2.6 mg/kg (up to a maximum dose of 270 mg) intravenous (IV) infusion of Nerinetide to subject with acute stroke who are selected for endovascular revascularization on serious adverse events (SAEs) and 90-day mortality. Trial Design: This study is a Phase 3, randomized, multicentre, blinded, placebo-controlled, parallel group, single-dose design. Subjects harboring an acute ischemic stroke and who are selected for endovascular revascularization in accordance with local institutional practices and who harbor a small established infarct core and with good collateral circulation will be given a single, 2.6 mg/kg (up to a maximum dose of 270 mg) intravenous dose of Nerinetide (NA-1) or placebo as soon as they are deemed to have met the enrollment criteria and with the intention of starting administration within 30 minutes of randomization. The randomization will be by stochastic minimization to balance baseline factors. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02930018
Study type	Interventional
Source	NoNO Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	March 1, 2017
Completion date	November 20, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05378035` - DOAC in Chinese Patients With Atrial Fibrillation
Completed	`NCT03574038` - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke	N/A
Completed	`NCT03679637` - Tablet-based Aphasia Therapy in the Acute Phase After Stroke	N/A
Completed	`NCT03633422` - Evaluation of Stroke Patient Screening
Completed	`NCT04088578` - VNS-supplemented Motor Retraining After Stroke	N/A
Withdrawn	`NCT04991038` - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients	N/A
Not yet recruiting	`NCT05534360` - Tenecteplase Treatment in Ischemic Stroke Registry
Not yet recruiting	`NCT04105322` - Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients	N/A
Withdrawn	`NCT05786170` - ERILs Und SNILs Unter SOC	N/A
Recruiting	`NCT03132558` - Contrast Induced Acute Kidney in Patients With Acute Stroke	N/A
Completed	`NCT02893631` - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Active, not recruiting	`NCT02274727` - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Completed	`NCT02225730` - Imaging Collaterals in Acute Stroke (iCAS)
Terminated	`NCT01705353` - The Role of HMGB-1 in Chronic Stroke	N/A
Active, not recruiting	`NCT01581502` - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)	N/A
Completed	`NCT01182818` - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease	N/A
Completed	`NCT00761982` - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment.	Phase 1/Phase 2
Completed	`NCT00535197` - Autologous Bone Marrow Stem Cells in Ischemic Stroke.	Phase 1/Phase 2
Terminated	`NCT00132509` - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke	Phase 2
Recruiting	`NCT05760326` - Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke — ESCAPE-NA1

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms